Evidence map›Paper›PMID 30215232›Full record

ArticleAnnals of laboratory medicine2019

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.

Zhan Qing Zhang, Yan Bing Wang, Wei Lu, Dan Ping Liu, Bi Sheng Shi, Xiao Nan Zhang, Dan Huang, Xiu Fen Li, Xin Lan Zhou, Rong Rong Ding

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Observational
  2. Review
  3. [Natural history and disease progression of chronic hepatitis B virus infection].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhan Qing Zhang *Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China. doctorzzqsphc@163.com.ORCID https://orcid.org/0000-0001-7709-9027
Yan Bing Wang *Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Wei LuDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Dan Ping LiuDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Bi Sheng ShiResearch Unit, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Xiao Nan ZhangResearch Unit, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Dan HuangDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Xiu Fen LiDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Xin Lan ZhouDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Rong Rong DingDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CN

Funding

National Natural Science Foundation of China 81671998National Science and Technology Major Project of China 2013ZX10002005Science and Technology Commission of Shanghai Municipality 16411960100Shanghai Municipal Health and Family Planning Commission 20134032
6 · The paper itself

Abstract

backgroundWe examined changes in hepatitis B core-related antigen (HBcrAg) during the four sequential phases of chronic hepatitis B virus (HBV) infection: hepatitis B e antigen (HBeAg)-positive chronic infection (EPCI) and hepatitis (EPCH), followed by HBeAg-negative chronic infection (ENCI) and hepatitis (ENCH). We compared the performance of serum HBcrAg, hepatitis B surface antigen (HBsAg), and HBV DNA in predicting EPCH and ENCH.

methodsWe enrolled 492 consecutive patients: 49 with EPCI, 243 with EPCH, 101 with ENCI, and 99 with ENCH. HBcrAg was detected by chemiluminescent enzyme immunoassays. HBsAg and HBeAg were detected by chemiluminescent microparticle immunoassays. HBV DNA was detected by real-time PCR. Predictive performance of HBcrAg, HBsAg, and HBV DNA was evaluated using ROC curves.

resultsAreas under ROC curves (AUCs) of HBcrAg, HBsAg, and HBV DNA for predicting EPCH were 0.738, 0.812, and 0.717, respectively; optimal cutoffs were ≤1.43×10⁵ kU/mL, ≤1.89×10⁴ IU/mL, and ≤3.97×10⁷ IU/mL, with sensitivities and specificities of 66.3% and 77.6%, 65.0% and 93.9%, and 60.5% and 79.6%, respectively. AUCs of HBcrAg, HBsAg, and HBV DNA for predicting ENCH were 0.887, 0.581, and 0.978, respectively; optimal cutoffs were >26.8 kU/mL, >2.29×10² IU/mL, and >8.75×10³ IU/mL, with sensitivities and specificities of 72.7% and 95.1%, 86.9% and 39.6%, and 89.9% and 92.1%, respectively.

conclusionsHBsAg and HBV DNA were the best predictors of EPCH and ENCH, respectively. HBcrAg is an important surrogate marker for predicting EPCH and ENCH.

Indexed as

AdolescentAdultAgedArea Under CurveDNA, ViralFemaleHepatitis B, ChronicHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoassayLuminescent MeasurementsMaleMiddle AgedDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensChronic hepatitis BHepatitis B core-related antigenHepatitis B surface antigenHepatitis B virus DNAPerformance

Identifiers

PMID30215232
PMCPMC6143474
OpenAlexW2891860944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.